Blog
RSS FeedPosted by Michael Wonder on 31 Mar 2022
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
31 March 2022 - EMA, in collaboration with the European Organisation for Research and Treatment of Cancer, has launched the Cancer ...
Posted by Michael Wonder on 30 Mar 2022
FDA officials aim to stop misuse of the term ‘digital biomarker’
29 March 2022 - While a lot of researchers claim they are capturing digital biomarker data, they may in fact be ...
Posted by Michael Wonder on 30 Mar 2022
Drug trials a ‘ticking time bomb’: ex-TGA agent
28 March 2022 - A former TGA official who led the regulator’s inspections program has warned that a lack of ...
Posted by Michael Wonder on 28 Mar 2022
2022 seasonal influenza vaccines
25 March 2022 - The Australian Influenza Vaccine Committee has reviewed data related to epidemiology, antigenic and genetic characteristics of recent ...
Posted by Michael Wonder on 24 Mar 2022
Pressured by patients, FDA reviews ALS drug with modest data
25 March 2022 - The FDA meets next week to review a closely watched drug for ALS, or Lou Gehrig’s ...
Posted by Michael Wonder on 23 Mar 2022
Medicago, Philip Morris and Health Canada: a predictable and avoidable fiasco
22 March 2022 - Health groups urge the Federal government to pressure Medicago to align its approach with that of ...
Posted by Michael Wonder on 22 Mar 2022
Pharmacy benefit managers are the wrong target In Biden’s quest to reduce drug prices
21 March 2022 - Prescription drug prices remain high despite the fact that the Biden Administration—and its predecessors—have declared reducing prices ...
Posted by Michael Wonder on 21 Mar 2022
China’s NMPA grants greater access to rheumatology biosimilars
22 March 2022 - Since the start of 2022, China’s National Medicinal Products Agency has made strides to increase greater ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...
Posted by Michael Wonder on 17 Mar 2022
Panel scrutinises quick FDA drug approvals
17 March 2022 - A House committee will spotlight an FDA process that’s been criticised as putting some of the ...
Posted by Michael Wonder on 17 Mar 2022
Agreement reached on funding reforms for medical devices
17 March 2022 - The Medical Technology Association of Australia has signed a joint four-year agreement with the Commonwealth Government ...
Posted by Michael Wonder on 17 Mar 2022
Reforms to deliver lower prices for medical devices and lower private health insurance premiums
17 March 2022 - The Australian Government’s plan to make private health insurance simpler and more affordable for all Australians is ...
Posted by Michael Wonder on 15 Mar 2022
1 April 2022 price disclosure confirmed prices
15 March 2022 - Confirmed 1 April 2022 prices resulting from the 2022 April cycle of price disclosure have now been ...
Posted by Michael Wonder on 12 Mar 2022
Catalyst Pharmaceuticals and KYE Pharmaceuticals announce a second favourable Canadian Federal Court ruling setting aside approval of Ruzurgi
11 March 2022 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced receipt of a favourable decision from the Federal Court of ...
Posted by Michael Wonder on 11 Mar 2022
In New York appearance, CMS administrator pushes for Congress to act on drug prices
11 March 2022 - When Chiquita Brooks-LaSure, the Biden official who oversees the Medicare and Medicaid health insurance programs, sat ...